Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

  • STATUS
    Recruiting
  • End date
    Jul 30, 2026
  • participants needed
    150
  • sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Updated on 30 September 2021

Summary

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

Description

Eligible patients are those who have progressive disease after treatment with Abi either in combination with ADT as initial therapy or as second-line therapy after development of resistance to primary ADT. Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production. Patients will be randomized 1:2:2 and stratified based on whether they received Abi in combination with ADT or in sequence after progression on ADT and based on duration of response to Abi (<6 or 6 months).

Patients randomized to Arm A will receive continuous therapy with standard dose Enza (160 mg po q day).

Patients randomized to Arm B will receive Sequential Testosterone and Enzalutamide (STE). Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). This dose was selected based on data demonstrating that it produces an initial high dose serum level of T (i.e. > 1500 ng/dL or 3-10 times normal level) with eugonadal levels achieved at the end of two weeks and near castrate levels after 28 days. On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.

Patients randomized to Arm C will receive Variable Sequential Testosterone and Enzalutamide (VSTE). Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at an FDA-approved dose of 400 mg every 28 days x 2 injections per cycle. Patients will remain on high dose T for at least one cycle. Each cycle is 56 days. Patients with declining PSA will remain on high dose T for additional cycles of 2 injections until PSA progression occurs based on PCWG3 criteria. Patients with PSA progression (25% increase in PSA from baseline) will stop T injection. These patients will then be started on Enzalutamide. Patients on enzalutamide with PSA decline after one 56 day cycle will continue on Enzalutamide until PSA progression occurs. Patients with PSA progression (25% increase in PSA from baseline) will stop Enzalutamide and will restart injections of T with 2 injections/cycle. These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.

Patients will have prostate-specific antigen (PSA) level and symptoms assessment checked every cycle. Every 2 cycles (~4 months) patients will have repeat bone/CT scans to evaluate treatment response status. On CT scan, radiographic progression will be defined by RECIST criteria (i.e. >20% increase in the sum of target lesions). On bone scan, radiographic progression will be defined by PCWG3 criteria as 2 new bone lesions.

Patients with PSA progression but with disease response or stable disease on imaging studies will remain on study until clinical or radiographic progression criteria are met. Patients with radiographic disease progression will stop treatment and come off study. Patients with clinical progression due to pain flare after first two injection of testosterone can remain on study. If pain persists after first cycle of enzalutamide, patients will stop treatment and come off study. If pain resolves on enzalutamide, but returns with next or subsequent cycles of testosterone, patients will stop treatment and come off study.

Details
Condition Castration Resistant Metastatic Prostate Cancer
Treatment Enzalutamide, testosterone enanthate, Testosterone cypionate
Clinical Study IdentifierNCT04363164
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last Modified on30 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

ECOG Performance status 2
Age 18 years
Histologically-confirmed adenocarcinoma of the prostate
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist)
Documented castrate level of serum testosterone (<50 ng/dl)
Metastatic disease radiographically documented by CT or bone scan
Must have had disease progression while on combination of abiraterone acetate plus ADT either given concurrently or sequentially based on
PSA progression defined as an increase in PSA, as determined by 2 separate measurements taken at least 1 week apart And/ Or
Radiographic disease progression, based on RECIST 1.1 in patients with measurable soft tissue lesions or PCWG3 for patients with bone disease
Screening PSA must be 1.0 ng/mL
Patients with soft tissue lesion amenable to biopsy must agree to biopsy collection pre-treatment and at a defined point on treatment to perform tumor tissue analysis
No prior treatment with enzalutamide, apalutamide, darolutamide, or other investigational AR targeted treatment is allowed
Prior treatment with testosterone is allowed
Prior treatment with one chemotherapy regimen with docetaxel ( 6 doses) for hormonesensitive prostate cancer is allowed
Prior treatment with Provenge vaccine and 223Radium (Xofigo) is allowed if >4 weeks from last dose
Patients must be withdrawn from abiraterone for 2 weeks
Attempts must be made to wean patients off prednisone and be off therapy for 1 week prior to starting therapy. Patients who cannot be weaned due to symptoms may continue on lowest dose of prednisone achieved during weaning period
Acceptable liver function
Bilirubin < 2.5 times institutional upper limit of normal (ULN)
AST (SGOT) and ALT (SGPT) < 2.5 times ULN
Acceptable renal function
Serum creatinine < 2.5 times ULN
Acceptable hematologic status
Absolute neutrophil count (ANC) 1500 cells/mm3 (1.5 109/L)
Platelet count 100,000 platelet/mm3 (100 109/L)
Hemoglobin 8 g/dL
At least 4 weeks since prior radiation or chemotherapy
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

Pain due to metastatic prostate cancer requiring treatment intervention with pain medication
ECOG Performance status 3
Prior treatment with enzalutamide is prohibited
Prior chemotherapy with docetaxel or cabazitaxel for castration resistant prostate cancer is prohibited
Requires urinary self-catheterization for voiding due to obstruction secondary to prostatic enlargement well documented to be due to prostate cancer or benign prostatic hyperplasia (BPH). Patients with indwelling Foley or suprapubic catheter for obstructive symptoms are eligible
Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, severe and extensive spinal metastases with concern over spinal cord compression, extensive liver metastases)
Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C
Any condition or mental impairment that may compromise the ability to give informed consent, patient's safety or compliance with study requirements as determined by the investigator
Patients receiving anticoagulation therapy with warfarin, rivaroxaban, or apixaban are not eligible for study. [Patients on enoxaparin eligible for study. Patients on warfarin, rivaroxaban,or apixaban, who can be transitioned to enoxaparin prior to starting study treatments will be eligible]
Patients are excluded with prior history of a thromboembolic event within the last 12 months that are not being treated with systemic anticoagulation
Hematocrit >51%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure [per Endocrine Society Clinical Practice Guidelines (34)]
Patients allergic to sesame seed oil or cottonseed oil are excluded
Major surgery (eg, requiring general anesthesia) within 3 weeks before screening, or has not fully recovered from prior surgery (ie, unhealed wound). Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note